NCT05250011 - Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions

Heart Failure, Reduced Ejection Fraction

Interventions

DRUG

Dapagliflozin

Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.

Trial Locations (11)

16132

Research Site, Genova

20122

Research Site, Milan

20900

Research Site, Monza

25123

Research Site, Brescia

34125

Research Site, Trieste

50100

Research Site, Florence

71122

Research Site, Foggia

80131

Research Site, Napoli

88100

Research Site, Catanzaro

00163

Research Site, Roma

00189

Research Site, Roma